1.Validation of the Japanese Version of the Quality of Life after Brain Injury (QOLIBRI) Scale
Megumi SUZUKI ; Mariko NAITO ; Kikuo OTA ; Klaus R H VON WILD ; Eiichi SAITOH ; Izumi KONDO
Brain & Neurorehabilitation 2019;12(2):e18-
The goal of the present study was to test the reliability and validity of the Japanese version of the Quality of Life after Brain Injury (QOLIBRI) scale. Correlations between the QOLIBRI and Glasgow Coma Scale scores, anxiety, depression, general quality of life (QOL), and demographic characteristics were examined to assess scale validity. The structure of the QOLIBRI was investigated with exploratory and confirmatory factor analyses, as well as the Partial Credit Model. Test–retest reliability was assessed over a 2-week interval. Participants were 129 patients with traumatic brain injury (TBI) recruited from rehabilitation centers in Japan. The QOLIBRI showed good-to-excellent internal consistency (Cronbach's α: 0.82–0.96), test–retest reliability, and validity (r = 0.77–0.90). Factor analyses revealed a 6-factor structure. Compared to an international sample (IS), Japanese patients had lower QOLIBRI scores and lower satisfaction in several domains. There were positive correlations between the QOLIBRI scales and the Short Form 36 Health Survey (r = 0.22–0.41). The Japanese version of the QOLIBRI showed good-to-excellent psychometric properties. Differences between JS and IS may reflect sampling bias and cultural norms regarding self-evaluation. The QOLIBRI could be a useful tool for assessing health-related QOL in individuals with TBI.
Anxiety
;
Asian Continental Ancestry Group
;
Brain Injuries
;
Brain
;
Depression
;
Diagnostic Self Evaluation
;
Glasgow Coma Scale
;
Health Surveys
;
Humans
;
Japan
;
Psychometrics
;
Quality of Life
;
Rehabilitation Centers
;
Reproducibility of Results
;
Selection Bias
;
Weights and Measures
2.Abstracts from japanese journal of hygiene (Nihoneiseigakuzasshi) Vol.52 No.2.
J Su LEE ; K KAWAKUBO ; A GUNJI ; K KAWABATA ; M IMAKI ; M OHGURT ; H KONDO ; Y HAYASHI ; S TANADA ; T KISHIDA ; R INABA ; H IWATA ; M AKISAKA ; H ZAKOUJI ; M ARIIZUMI ; I FUKUNAGA ; F JITSUNARI ; N TAKEDA ; F ASAKAWA ; Y MARUYAMA ; Y HIGAKI ; N SHONO ; M NISHIZUMI ; T TSUDA ; Y MINO ; E YAMAMOTO ; H MATSUOKA ; A BABAZONO ; J SHIGEMI ; M MIYAI
Environmental Health and Preventive Medicine 1997;2(2):93-98
3.Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives.
Mahmood A HAMED ; Seiichi NAKATA ; Ramadan H SAYED ; Hiromi UEDA ; Badawy S BADAWY ; Yoichi NISHIMURA ; Takuro KOJIMA ; Noboru IWATA ; Ahmed R AHMED ; Khalid DAHY ; Naoki KONDO ; Kenji SUZUKI
Clinical and Experimental Otorhinolaryngology 2016;9(4):298-308
Cholesteatoma is a cystic non tumorous lesion of the temporal bone that has the ability to destroy nearby structures by its power to cause bone resorption and as a result, fatal complications prevail. We aimed to conduct a comprehensive review for pathogenesis of acquired cholesteatoma, bone resorption mechanisms, and offer a future vision of this serious disease. We have reviewed different theories for pathogenesis of acquired cholesteatoma including the most relevant and updated ones with special emphasis on the mechanisms of bone resorption through Medline/PubMed research using the keywords ‘aetiopathogenesis, bone resorption, acquired cholesteatoma, temporal bone, and cytokines.’ In order to strengthen our study, we searched the reference lists of identified reviews. Cholesteatoma is a subject of debate among otolaryngologists since it was prescribed firstly. Over many decades, several theories were postulated for aetiopathogenesis of cholesteatoma with a tendency to follow more than one theory to explain the proper nature of that disease. Until now, the mechanism of bone resorption has yet to be more clarified. In the last century, a leap has occurred in the field of biomolecular cholesteatoma research which improved our knowledge about its pathophysiology and bone destructive mechanism. However, surgery is still the only available treatment. We conclude that discovery of new therapeutic choices for cholesteatoma other than surgery by the use of anti-growth, anti-proliferative, apoptotic agents as well as medications that antagonize osteoclastogenesis should be the main concern in the future clinical and experimental research work. Also, searching for predictors of the aggressiveness of cholesteatoma can affect the timing of intervention and prevent occurrence of complications.
Bone Resorption*
;
Cholesteatoma*
;
Cytokines
;
Temporal Bone